The Zhitong Finance App learned that CMB International released a research report stating that the ADC platform of Hanson Pharmaceuticals (03692.HK) has received important verification in terms of both cooperation and clinical trials. The bank reaffirmed the “buy” rating and raised the target price from HK$49.12 to HK$50.54.

The Zhitong Finance App learned that CMB International released a research report stating that the ADC platform of Hanson Pharmaceuticals (03692.HK) has received important verification in terms of both cooperation and clinical trials. The bank reaffirmed the “buy” rating and raised the target price from HK$49.12 to HK$50.54.